MilliporeSigma
在场
是其中之一......
Merck KGaA 是一家在股票代码 MRK (DE) 下上市的公司。
Merck KGaA 在 17 个国家有直接业务。Merck KGaA 拥有 21家子公司，其中包括 Asceneuron、EMD Serono 和 Intermolecular。
他们在：
涉及Merck KGaA的并购和融资。
- MilliporeSigma has announced the acquisition of MiRus (公布2024八月1号).
高管
查看带有其 15 名主要高管的组织结构图
MilliporeSigma 搜索最多的简介
- Matthias Heinzel, Chief Executive Officer
- Ivan Donzelot, Executive Vice President, Supply Chain Operations
- Bart Kerkman, Chief Information Officer
创建提醒
跟踪 MilliporeSigma 的高管变动
生物技术
Merck KGaA 拥有 2,317 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
MilliporeSigma 的最新新闻稿
- Merck Announces Proteologix as Winner of its North American Advance Biotech GrantBack ButtonFilter Button
- Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine ManufacturersBack ButtonFilter Button
- Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in ScotlandBack ButtonFilter Button
- Merck Invests Approximately € 70 Million to Expand Reagent Manufacturing in ChinaBack ButtonFilter Button
- Merck Increases Global Commitment to Biosafety Testing With € 35 Million Investment in ScotlandBack ButtonFilter Button
- Merck Announces Proteologix as Winner of its North American Advance Biotech GrantBack ButtonFilter Button
- Merck Study: mRNA Technology a ‘Game Changer’ for Asia-Pacific Vaccine ManufacturersBack ButtonFilter Button
- Merck Invests Approximately € 70 Million to Expand Reagent Manufacturing in ChinaBack ButtonFilter Button
- Merck Opens €59 Million CDMO Facility to Address Demand for Critical Cancer Therapies
- Press Releases | Merck
- View more press releases Close
关于 MilliporeSigma 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Bart Kerkman 
